Medical Breakthroughs

Founder-Led AI: Evidence to Net Revenue Retention in Cardiac

Listen to this article · 6 min listen

In healthcare AI, the investment game is no longer about who raises the most capital. It’s about who can actually convert clinical evidence into sustainable commercial traction. For venture investors and for founders trying to build a diagnostic AI company, that’s the only thing that matters. The real scorecard for a founder in this space is net revenue retention, because that metric tells you directly if your strong clinical validation is creating durable commercial accounts or just gathering dust.

Funding and the Foundation of Evidence

Cleerly hit a big financial milestone in December 2024, raising a $106 million Series C extension. The round was led by Insight Partners, and Battery Ventures was also in the mix. That kind of money shows investors believe in what they’re doing with coronary plaque analysis. But for any diagnostic AI business, capital is just the fuel. The engine is the hard evidence you build to prove the technology works.

Cleerly’s new funding goes right into its coronary plaque analysis program, which has already been put through the wringer in trials like CREDENCE. The whole investment thesis for companies like this rests on their ability to generate high-quality clinical data that proves efficacy and safety, which in turn de-risks the brutal path to commercialization. Building that evidence file isn’t a one-time event. It’s a continuous process that demands cash and a clear strategy.

The CREDENCE Trial: A Benchmark for Clinical Validation

The CREDENCE trial is exactly the kind of data point we use to evaluate Cleerly’s clinical validation. Its per-vessel analysis came back with a sensitivity of 75.9 percent and a specificity of 83.4 percent. To make the case even stronger, a pooled analysis covering 582 patients and 1,521 vessels showed a 76.2 percent sensitivity and 85.2 percent specificity. Venture investors need to see numbers like these to feel comfortable with the clinical utility and accuracy of a diagnostic tool. CREDENCE trial results publication

In diagnostic AI, these metrics have teeth. They directly impact a company’s regulatory risk rating and how deep its penetration with payers can go. High sensitivity and specificity are the table stakes for getting regulatory clearance and then convincing payers that your tech will improve patient outcomes (and maybe even lower their costs). The rigor of a trial like CREDENCE sets the bar for what counts as credible evidence for anyone else trying to enter the coronary plaque analysis space.

Working through the Payer Field

The path from a good clinical trial to a successful commercial product runs straight through the payer field. For Cleerly, this means grappling with the coding records at places like WPS Government Health Administrators, because those policies determine how its coronary plaque analysis work actually gets paid for. A huge part of a diagnostic AI company’s strategy is just figuring out how to understand and influence those codes.

Payer penetration depth is one of the first things we look at in a healthcare AI investment. Companies have to show us a clear route to reimbursement, which almost always involves working through complex coding structures and proving economic value on top of clinical efficacy. The ability to secure favorable coding and coverage decisions is a powerful signal of a company’s potential to generate sustainable revenue. Without that piece, even the most impressive, clinically validated AI will struggle to get adopted.

The Founder’s Metric: Evidence Conversion to Net Revenue Retention

When we’re evaluating a founder in the diagnostic AI business, we don’t really care about the size of their funding rounds or the impressiveness of their clinical trial data in a vacuum. What we care about is their ability to turn that evidence into durable commercial accounts, and the best way to measure that is with net revenue retention (NRR). NRR shows whether your customers stick around and, more importantly, if they expand their use of your product over time.

A strong NRR in healthcare AI is the ultimate proof that the entire chain is working, the clinical validation, the regulatory wins, and the payer contracts are all successfully converting into consistent, growing revenue streams. It tells you the AI solution is actually baked into clinical workflows, that it’s delivering tangible value to providers and patients, and that its benefits are real enough for customers to keep paying for them. This single metric gives you a full picture of commercial viability and market acceptance, linking the scientific work directly to the financial health of the business.

Founders who spend their time painstakingly building their evidence records, fighting through regulatory complexity, and strategically engaging with payers are all aiming for this conversion. In the end, a founder’s record isn’t judged on the scientific novelty of their AI. It’s judged on its successful integration into the healthcare economy to create a sustainable, scalable business model. Focusing on evidence conversion as the main founder metric gives everyone a clear framework for judging the long-term potential of any healthcare AI company.

Frequently Asked Questions

What is the ultimate measure of a founder’s success in a diagnostic AI business for venture investors?

The ultimate measure of a founder’s success is their ability to convert clinical evidence into durable commercial accounts, best reflected by net revenue retention (NRR). NRR demonstrates if customers are retained and expanding their engagement with the product over time, indicating effective translation of clinical validation, regulatory approvals, and payer coverage into consistent, growing revenue streams.

How does clinical evidence, such as trial results, influence the commercialization pathway for diagnostic AI?

High-quality clinical data, like the CREDENCE trial’s sensitivity and specificity figures, de-risks the commercialization pathway by proving efficacy and safety. These metrics directly influence regulatory risk rating and payer penetration depth, which are foundational for gaining regulatory clearances and convincing payers of the technology’s value.

What role do payer coding records play in the commercial success of diagnostic AI solutions?

Payer coding records, such as those from WPS Government Health Administrators, are crucial for shaping how diagnostic AI work reaches payment. Understanding and influencing these coding records is a critical component of a diagnostic AI company’s strategy, as securing favorable coding and coverage decisions is a strong indicator of potential for sustainable revenue generation.

Beyond funding, what is the ‘engine’ for diagnostic AI businesses?

For diagnostic AI businesses, capital infusion is merely the fuel; the engine is the rigorous evidence base that underpins the technology. This evidence building is a continuous process requiring sustained investment and strategic execution to generate and leverage high-quality clinical data to prove efficacy and safety.

Share
Was this article helpful?

Editorial Team

The Editorial Team at Healthcare AI Investor Guide is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.